These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 36811789

  • 1. Outcomes of immune checkpoint inhibitors for postoperative recurrence of non-small cell lung cancer.
    Yuasa I, Hamaji M, Ozasa H, Sakamori Y, Yoshida H, Yutaka Y, Menju T, Hirai T, Date H.
    Gen Thorac Cardiovasc Surg; 2023 Sep; 71(9):534-541. PubMed ID: 36811789
    [Abstract] [Full Text] [Related]

  • 2. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT, Su CT, Hu M, Taylor JMG, Daignault-Newton S, Kellezi O, Dahl MN, Shah MA, Erickson S, Lora J, Hamasha R, Ali A, Yancey S, Kiros L, Balicki HM, Winfield DC, Green MD, Alva AS.
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [Abstract] [Full Text] [Related]

  • 3. The clinical impact of concomitant medication use on the outcome of postoperative recurrent non-small-cell lung cancer in patients receiving immune checkpoint inhibitors.
    Takada K, Shimokawa M, Takamori S, Shimamatsu S, Hirai F, Ono Y, Tagawa T, Okamoto T, Hamatake M, Okamoto I, Mori M.
    PLoS One; 2022 Jul; 17(2):e0263247. PubMed ID: 35130287
    [Abstract] [Full Text] [Related]

  • 4. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
    Ochi N, Ichihara E, Takigawa N, Harada D, Inoue K, Shibayama T, Hosokawa S, Kishino D, Harita S, Oda N, Hara N, Hotta K, Maeda Y, Kiura K.
    Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
    [Abstract] [Full Text] [Related]

  • 5. Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11).
    Kim H, Kim DW, Kim M, Lee Y, Ahn HK, Cho JH, Kim IH, Lee YG, Shin SH, Park SE, Jung J, Kang EJ, Ahn MJ.
    Cancer; 2022 Feb 15; 128(4):778-787. PubMed ID: 34705268
    [Abstract] [Full Text] [Related]

  • 6. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Chen H, Han KD, He ZJ, Huang YS.
    Technol Cancer Res Treat; 2021 Feb 15; 20():15330338211033498. PubMed ID: 34323149
    [Abstract] [Full Text] [Related]

  • 7. The efficacy of immune checkpoint inhibitors in advanced EGFR-Mutated non-small cell lung cancer after resistance to EGFR-TKIs: Real-World evidence from a multicenter retrospective study.
    Hu J, Huang D, Wang Y, Li D, Yang X, Fu Y, Du N, Zhao Y, Li X, Ma J, Hu Y.
    Front Immunol; 2022 Feb 15; 13():975246. PubMed ID: 36159795
    [Abstract] [Full Text] [Related]

  • 8. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
    Kawachi H, Yamada T, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Ishida M, Katayama Y, Morimoto K, Iwasaku M, Tokuda S, Kijima T, Takayama K.
    JAMA Netw Open; 2023 Jul 03; 6(7):e2322915. PubMed ID: 37432682
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of Immune Checkpoint Inhibitors in Postoperative Recurrence of Wild-type EGFR Non-Small Cell Lung Cancer.
    Imamura Y, Kato T, Nomata Y, Okado S, Watanabe H, Kawasumi Y, Nakanishi K, Kadomatsu Y, Ueno H, Nakamura S, Mizuno T, Hase T, Tanaka I, Ishii M, Yatsuya H, Chen-Yoshikawa TF.
    Anticancer Res; 2024 Aug 03; 44(8):3451-3461. PubMed ID: 39060057
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Evaluating Oral Probiotic Supplements as Complementary Treatment in Advanced Lung Cancer Patients Receiving ICIs: A Prospective Real-World Study.
    Tong L, Wan Y, Shi X, Liu X, Liu Z, Li Y, Zhang Y, Luo D, Zhu J.
    Cancer Control; 2024 Aug 03; 31():10732748241253959. PubMed ID: 38736182
    [Abstract] [Full Text] [Related]

  • 13. Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations.
    Si J, Hao Y, Wei J, Xiang J, Xu C, Shen Q, Song Z.
    BMC Pulm Med; 2023 May 05; 23(1):158. PubMed ID: 37147602
    [Abstract] [Full Text] [Related]

  • 14. Effect of Stereotactic Body Radiation Therapy on Diverse Organ Lesions in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
    Zhu KK, Wei JL, Xu YH, Li J, Rao XR, Xu YZ, Xing BY, Zhang SJ, Chen LC, Dong XR, Zhang S, Li ZY, Liu CW, Meng R, Wu G.
    Curr Med Sci; 2023 Apr 05; 43(2):344-359. PubMed ID: 37002471
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
    Zheng MM, Tu HY, Yang JJ, Zhang XC, Zhou Q, Xu CR, Jiang BY, Yang XN, Yang XR, Deng JY, Yang MY, Xu BF, Chen XM, Li YS, Wu YL.
    Eur J Cancer; 2021 Jun 05; 150():23-30. PubMed ID: 33882375
    [Abstract] [Full Text] [Related]

  • 17. Management and outcomes of non-small cell lung cancer patients with rapid progression under second-or-more-line immune checkpoint inhibitors: ERORECI study (GFPC 2016-04).
    Vergnenegre A, Geier M, Guisier F, Lamy R, Comet B, Le Garff G, Do P, Janicot H, Morel H, Decroisette C, Andre M, Falchero L, Paleiron N, Monnet I, GFPC Team.
    Cancer Med; 2020 Jan 05; 9(2):432-439. PubMed ID: 31747137
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.